Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the safety and best dose of binimetinib when given in combination
with docetaxel in treating patients with previously treated, stage IV non-small cell lung
cancer. Binimetinib and docetaxel may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals